Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study
Identifieur interne : 005D23 ( Main/Exploration ); précédent : 005D22; suivant : 005D24Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study
Auteurs : Judith M. Bliss [Royaume-Uni] ; Lucy S. Kilburn [Royaume-Uni] ; Robert E. Coleman [Royaume-Uni] ; John F. Forbes [Australie] ; Alan S. Coates [Suisse, Australie] ; Stephen E. Jonas [États-Unis] ; Jacek Jassem [Pologne] ; Thierry Delozier [France] ; J Rn Andersen [Danemark] ; Robert Paridaens [Belgique] ; Cornelis J. H. Van De Velde [Pays-Bas] ; Per E. Lonning [Norvège] ; James Morden [Royaume-Uni] ; Justine Reise [Royaume-Uni] ; Laura Cisar [États-Unis] ; Thomas Menschik [France] ; R. Charles Coombes [Royaume-Uni]Source :
- Journal of clinical oncology [ 0732-183X ] ; 2012.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
Purpose Intergroup Exemestane Study (IES), an investigator-led study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically important benefits from switching adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane. Now, with longer follow-up, a large number of non-breast cancer-related events have been reported. Exploratory analyses describe breast cancer-free survival (BCFS) and explore incidence and patterns of the different competing events. Patients and Methods Patients who were disease-free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete 5 years of adjuvant endocrine therapy. At this planned analysis, the median follow-up was 91 months. Principal analysis focuses on 4,052 patients with estrogen receptor (ER) -positive and 547 with ER-unknown tumors. Results In all, 930 BCFS events have been reported (exemestane, 423; tamoxifen, 507), giving an unadjusted hazard ratio (HR) of 0.81 (95% CI, 0.71 to 0.92; P = .001) in favor of exemestane in the ER-positive/ER unknown group. Analysis partitioned at 2.5 years after random assignment showed that the on-treatment benefit of switching to exemestane (HR, 0.60; 95% CI, 0.48 to 0.75; P < .001) was not lost post-treatment, but that there was no additional gain once treatment had ceased (HR, 0.94; 95% CI, 0.80 to 1.10; P = .60). Improvement in overall survival was demonstrated, with 352 deaths in the exemestane group versus 405 deaths in the tamoxifen group (HR, 0.86; 95% CI, 0.75 to 0.99; P = .04). Of these, 222 were reported as intercurrent deaths (exemestane, 107; tamoxifen, 115). Conclusion The protective effect of switching to exemestane compared with continuing on tamoxifen on risk of relapse or death was maintained for at least 5 years post-treatment and was associated with a continuing beneficial impact on overall survival.
Affiliations:
- Australie, Belgique, Danemark, France, Norvège, Pays-Bas, Pologne, Royaume-Uni, Suisse, États-Unis
- Angleterre, Basse-Normandie, Canton de Berne, Grand Londres, Hollande-Méridionale, Nouvelle-Galles du Sud, Région Normandie, Île-de-France
- Berne, Caen, Leyde, Londres, Paris, Sydney
- Université de Sydney
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001550
- to stream PascalFrancis, to step Curation: 004962
- to stream PascalFrancis, to step Checkpoint: 001201
- to stream Main, to step Merge: 006036
- to stream Main, to step Curation: 005D23
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study</title><author><name sortKey="Bliss, Judith M" sort="Bliss, Judith M" uniqKey="Bliss J" first="Judith M." last="Bliss">Judith M. Bliss</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Institute of Cancer Research</s1><s2>Sutton</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>The Institute of Cancer Research</wicri:noRegion></affiliation></author><author><name sortKey="Kilburn, Lucy S" sort="Kilburn, Lucy S" uniqKey="Kilburn L" first="Lucy S." last="Kilburn">Lucy S. Kilburn</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Institute of Cancer Research</s1><s2>Sutton</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>The Institute of Cancer Research</wicri:noRegion></affiliation></author><author><name sortKey="Coleman, Robert E" sort="Coleman, Robert E" uniqKey="Coleman R" first="Robert E." last="Coleman">Robert E. Coleman</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Weston Park Hospital</s1><s2>Sheffield</s2><s3>GBR</s3><sZ>3 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Weston Park Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Forbes, John F" sort="Forbes, John F" uniqKey="Forbes J" first="John F." last="Forbes">John F. Forbes</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Newcastle, Newcastle Mater Hospital</s1><s2>Newcastle, New South Wales</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Newcastle, New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>International Breast Cancer Study Group</s1><s2>Bern</s2><s3>CHE</s3><sZ>5 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>University of Sydney</s1><s2>Sydney</s2><s3>AUS</s3><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Jonas, Stephen E" sort="Jonas, Stephen E" uniqKey="Jonas S" first="Stephen E." last="Jonas">Stephen E. Jonas</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>US Oncology Research</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>US Oncology Research</wicri:noRegion></affiliation></author><author><name sortKey="Jassem, Jacek" sort="Jassem, Jacek" uniqKey="Jassem J" first="Jacek" last="Jassem">Jacek Jassem</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Medical University of Gdansk</s1><s2>Gdansk</s2><s3>POL</s3><sZ>7 aut.</sZ></inist:fA14><country>Pologne</country><wicri:noRegion>Medical University of Gdansk</wicri:noRegion></affiliation></author><author><name sortKey="Delozier, Thierry" sort="Delozier, Thierry" uniqKey="Delozier T" first="Thierry" last="Delozier">Thierry Delozier</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Centre Francois Baclesse</s1><s2>Caen</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Région Normandie</region><region type="old region">Basse-Normandie</region><settlement type="city">Caen</settlement></placeName></affiliation></author><author><name sortKey="Andersen, J Rn" sort="Andersen, J Rn" uniqKey="Andersen J" first="J Rn" last="Andersen">J Rn Andersen</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Aarhus University Hospital</s1><s2>Aarhus</s2><s3>DNK</s3><sZ>9 aut.</sZ></inist:fA14><country>Danemark</country><wicri:noRegion>Aarhus University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Paridaens, Robert" sort="Paridaens, Robert" uniqKey="Paridaens R" first="Robert" last="Paridaens">Robert Paridaens</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Universitair Ziekenhuis Gasthuisberg</s1><s2>Leuven</s2><s3>BEL</s3><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Universitair Ziekenhuis Gasthuisberg</wicri:noRegion></affiliation></author><author><name sortKey="De Velde, Cornelis J H Van" sort="De Velde, Cornelis J H Van" uniqKey="De Velde C" first="Cornelis J. H. Van" last="De Velde">Cornelis J. H. Van De Velde</name><affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Leiden University Medical Centre</s1><s2>Leiden</s2><s3>NLD</s3><sZ>11 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Lonning, Per E" sort="Lonning, Per E" uniqKey="Lonning P" first="Per E." last="Lonning">Per E. Lonning</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>University of Bergen and Haukeland University Hospital</s1><s2>Bergen</s2><s3>NOR</s3><sZ>12 aut.</sZ></inist:fA14><country>Norvège</country><wicri:noRegion>University of Bergen and Haukeland University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Morden, James" sort="Morden, James" uniqKey="Morden J" first="James" last="Morden">James Morden</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Institute of Cancer Research</s1><s2>Sutton</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>The Institute of Cancer Research</wicri:noRegion></affiliation></author><author><name sortKey="Reise, Justine" sort="Reise, Justine" uniqKey="Reise J" first="Justine" last="Reise">Justine Reise</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Justine Reise and R. Charles Coombes, Imperial College London</s1><s2>London</s2><s3>GBR</s3><sZ>14 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Cisar, Laura" sort="Cisar, Laura" uniqKey="Cisar L" first="Laura" last="Cisar">Laura Cisar</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Pfizer</s1><s2>New York, NY</s2><s3>USA</s3><sZ>15 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pfizer</wicri:noRegion></affiliation></author><author><name sortKey="Menschik, Thomas" sort="Menschik, Thomas" uniqKey="Menschik T" first="Thomas" last="Menschik">Thomas Menschik</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Pfizer Oncology Europe</s1><s2>Paris</s2><s3>FRA</s3><sZ>16 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Coombes, R Charles" sort="Coombes, R Charles" uniqKey="Coombes R" first="R. Charles" last="Coombes">R. Charles Coombes</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Justine Reise and R. Charles Coombes, Imperial College London</s1><s2>London</s2><s3>GBR</s3><sZ>14 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0121349</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0121349 INIST</idno><idno type="RBID">Pascal:12-0121349</idno><idno type="wicri:Area/PascalFrancis/Corpus">001550</idno><idno type="wicri:Area/PascalFrancis/Curation">004962</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001201</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001201</idno><idno type="wicri:doubleKey">0732-183X:2012:Bliss J:disease:related:outcomes</idno><idno type="wicri:Area/Main/Merge">006036</idno><idno type="wicri:Area/Main/Curation">005D23</idno><idno type="wicri:Area/Main/Exploration">005D23</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study</title><author><name sortKey="Bliss, Judith M" sort="Bliss, Judith M" uniqKey="Bliss J" first="Judith M." last="Bliss">Judith M. Bliss</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Institute of Cancer Research</s1><s2>Sutton</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>The Institute of Cancer Research</wicri:noRegion></affiliation></author><author><name sortKey="Kilburn, Lucy S" sort="Kilburn, Lucy S" uniqKey="Kilburn L" first="Lucy S." last="Kilburn">Lucy S. Kilburn</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Institute of Cancer Research</s1><s2>Sutton</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>The Institute of Cancer Research</wicri:noRegion></affiliation></author><author><name sortKey="Coleman, Robert E" sort="Coleman, Robert E" uniqKey="Coleman R" first="Robert E." last="Coleman">Robert E. Coleman</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Weston Park Hospital</s1><s2>Sheffield</s2><s3>GBR</s3><sZ>3 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Weston Park Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Forbes, John F" sort="Forbes, John F" uniqKey="Forbes J" first="John F." last="Forbes">John F. Forbes</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Newcastle, Newcastle Mater Hospital</s1><s2>Newcastle, New South Wales</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Newcastle, New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>International Breast Cancer Study Group</s1><s2>Bern</s2><s3>CHE</s3><sZ>5 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>University of Sydney</s1><s2>Sydney</s2><s3>AUS</s3><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Jonas, Stephen E" sort="Jonas, Stephen E" uniqKey="Jonas S" first="Stephen E." last="Jonas">Stephen E. Jonas</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>US Oncology Research</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>US Oncology Research</wicri:noRegion></affiliation></author><author><name sortKey="Jassem, Jacek" sort="Jassem, Jacek" uniqKey="Jassem J" first="Jacek" last="Jassem">Jacek Jassem</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Medical University of Gdansk</s1><s2>Gdansk</s2><s3>POL</s3><sZ>7 aut.</sZ></inist:fA14><country>Pologne</country><wicri:noRegion>Medical University of Gdansk</wicri:noRegion></affiliation></author><author><name sortKey="Delozier, Thierry" sort="Delozier, Thierry" uniqKey="Delozier T" first="Thierry" last="Delozier">Thierry Delozier</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Centre Francois Baclesse</s1><s2>Caen</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Région Normandie</region><region type="old region">Basse-Normandie</region><settlement type="city">Caen</settlement></placeName></affiliation></author><author><name sortKey="Andersen, J Rn" sort="Andersen, J Rn" uniqKey="Andersen J" first="J Rn" last="Andersen">J Rn Andersen</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Aarhus University Hospital</s1><s2>Aarhus</s2><s3>DNK</s3><sZ>9 aut.</sZ></inist:fA14><country>Danemark</country><wicri:noRegion>Aarhus University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Paridaens, Robert" sort="Paridaens, Robert" uniqKey="Paridaens R" first="Robert" last="Paridaens">Robert Paridaens</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Universitair Ziekenhuis Gasthuisberg</s1><s2>Leuven</s2><s3>BEL</s3><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Universitair Ziekenhuis Gasthuisberg</wicri:noRegion></affiliation></author><author><name sortKey="De Velde, Cornelis J H Van" sort="De Velde, Cornelis J H Van" uniqKey="De Velde C" first="Cornelis J. H. Van" last="De Velde">Cornelis J. H. Van De Velde</name><affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Leiden University Medical Centre</s1><s2>Leiden</s2><s3>NLD</s3><sZ>11 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Lonning, Per E" sort="Lonning, Per E" uniqKey="Lonning P" first="Per E." last="Lonning">Per E. Lonning</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>University of Bergen and Haukeland University Hospital</s1><s2>Bergen</s2><s3>NOR</s3><sZ>12 aut.</sZ></inist:fA14><country>Norvège</country><wicri:noRegion>University of Bergen and Haukeland University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Morden, James" sort="Morden, James" uniqKey="Morden J" first="James" last="Morden">James Morden</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Institute of Cancer Research</s1><s2>Sutton</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>The Institute of Cancer Research</wicri:noRegion></affiliation></author><author><name sortKey="Reise, Justine" sort="Reise, Justine" uniqKey="Reise J" first="Justine" last="Reise">Justine Reise</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Justine Reise and R. Charles Coombes, Imperial College London</s1><s2>London</s2><s3>GBR</s3><sZ>14 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Cisar, Laura" sort="Cisar, Laura" uniqKey="Cisar L" first="Laura" last="Cisar">Laura Cisar</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Pfizer</s1><s2>New York, NY</s2><s3>USA</s3><sZ>15 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pfizer</wicri:noRegion></affiliation></author><author><name sortKey="Menschik, Thomas" sort="Menschik, Thomas" uniqKey="Menschik T" first="Thomas" last="Menschik">Thomas Menschik</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Pfizer Oncology Europe</s1><s2>Paris</s2><s3>FRA</s3><sZ>16 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Coombes, R Charles" sort="Coombes, R Charles" uniqKey="Coombes R" first="R. Charles" last="Coombes">R. Charles Coombes</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Justine Reise and R. Charles Coombes, Imperial College London</s1><s2>London</s2><s3>GBR</s3><sZ>14 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term><term>Cancerology</term><term>Exemestane</term><term>Follow up study</term><term>Long term</term><term>Prognosis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Exémestane</term><term>Pronostic</term><term>Long terme</term><term>Etude longitudinale</term><term>Cancérologie</term><term>Anticancéreux</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose Intergroup Exemestane Study (IES), an investigator-led study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically important benefits from switching adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane. Now, with longer follow-up, a large number of non-breast cancer-related events have been reported. Exploratory analyses describe breast cancer-free survival (BCFS) and explore incidence and patterns of the different competing events. Patients and Methods Patients who were disease-free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete 5 years of adjuvant endocrine therapy. At this planned analysis, the median follow-up was 91 months. Principal analysis focuses on 4,052 patients with estrogen receptor (ER) -positive and 547 with ER-unknown tumors. Results In all, 930 BCFS events have been reported (exemestane, 423; tamoxifen, 507), giving an unadjusted hazard ratio (HR) of 0.81 (95% CI, 0.71 to 0.92; P = .001) in favor of exemestane in the ER-positive/ER unknown group. Analysis partitioned at 2.5 years after random assignment showed that the on-treatment benefit of switching to exemestane (HR, 0.60; 95% CI, 0.48 to 0.75; P < .001) was not lost post-treatment, but that there was no additional gain once treatment had ceased (HR, 0.94; 95% CI, 0.80 to 1.10; P = .60). Improvement in overall survival was demonstrated, with 352 deaths in the exemestane group versus 405 deaths in the tamoxifen group (HR, 0.86; 95% CI, 0.75 to 0.99; P = .04). Of these, 222 were reported as intercurrent deaths (exemestane, 107; tamoxifen, 115). Conclusion The protective effect of switching to exemestane compared with continuing on tamoxifen on risk of relapse or death was maintained for at least 5 years post-treatment and was associated with a continuing beneficial impact on overall survival.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>Danemark</li><li>France</li><li>Norvège</li><li>Pays-Bas</li><li>Pologne</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Basse-Normandie</li><li>Canton de Berne</li><li>Grand Londres</li><li>Hollande-Méridionale</li><li>Nouvelle-Galles du Sud</li><li>Région Normandie</li><li>Île-de-France</li></region><settlement><li>Berne</li><li>Caen</li><li>Leyde</li><li>Londres</li><li>Paris</li><li>Sydney</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Bliss, Judith M" sort="Bliss, Judith M" uniqKey="Bliss J" first="Judith M." last="Bliss">Judith M. Bliss</name></noRegion><name sortKey="Coleman, Robert E" sort="Coleman, Robert E" uniqKey="Coleman R" first="Robert E." last="Coleman">Robert E. Coleman</name><name sortKey="Coombes, R Charles" sort="Coombes, R Charles" uniqKey="Coombes R" first="R. Charles" last="Coombes">R. Charles Coombes</name><name sortKey="Kilburn, Lucy S" sort="Kilburn, Lucy S" uniqKey="Kilburn L" first="Lucy S." last="Kilburn">Lucy S. Kilburn</name><name sortKey="Morden, James" sort="Morden, James" uniqKey="Morden J" first="James" last="Morden">James Morden</name><name sortKey="Reise, Justine" sort="Reise, Justine" uniqKey="Reise J" first="Justine" last="Reise">Justine Reise</name></country><country name="Australie"><noRegion><name sortKey="Forbes, John F" sort="Forbes, John F" uniqKey="Forbes J" first="John F." last="Forbes">John F. Forbes</name></noRegion><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name></country><country name="Suisse"><region name="Canton de Berne"><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name></region></country><country name="États-Unis"><noRegion><name sortKey="Jonas, Stephen E" sort="Jonas, Stephen E" uniqKey="Jonas S" first="Stephen E." last="Jonas">Stephen E. Jonas</name></noRegion><name sortKey="Cisar, Laura" sort="Cisar, Laura" uniqKey="Cisar L" first="Laura" last="Cisar">Laura Cisar</name></country><country name="Pologne"><noRegion><name sortKey="Jassem, Jacek" sort="Jassem, Jacek" uniqKey="Jassem J" first="Jacek" last="Jassem">Jacek Jassem</name></noRegion></country><country name="France"><region name="Région Normandie"><name sortKey="Delozier, Thierry" sort="Delozier, Thierry" uniqKey="Delozier T" first="Thierry" last="Delozier">Thierry Delozier</name></region><name sortKey="Menschik, Thomas" sort="Menschik, Thomas" uniqKey="Menschik T" first="Thomas" last="Menschik">Thomas Menschik</name></country><country name="Danemark"><noRegion><name sortKey="Andersen, J Rn" sort="Andersen, J Rn" uniqKey="Andersen J" first="J Rn" last="Andersen">J Rn Andersen</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Paridaens, Robert" sort="Paridaens, Robert" uniqKey="Paridaens R" first="Robert" last="Paridaens">Robert Paridaens</name></noRegion></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="De Velde, Cornelis J H Van" sort="De Velde, Cornelis J H Van" uniqKey="De Velde C" first="Cornelis J. H. Van" last="De Velde">Cornelis J. H. Van De Velde</name></region></country><country name="Norvège"><noRegion><name sortKey="Lonning, Per E" sort="Lonning, Per E" uniqKey="Lonning P" first="Per E." last="Lonning">Per E. Lonning</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D23 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005D23 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:12-0121349
|texte= Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study
}}
| This area was generated with Dilib version V0.6.33. |  |